Deerfield Management’s VYNE Therapeutics VYNE Stock Holding History

Deerfield Management’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,384	Closed	-$446K	–	94
2019 Q3	$446K	Sell	1,384 -1,372	-50%	-$443K	0.02%	93
2019 Q2	$1.19M	Hold	2,756	–	–	0.04%	95
2019 Q1	$1.56M	Buy	+2,756	New	+$1.32M	0.06%	89
2018 Q2	–	Sell	-5,927	Closed	-$16M	–	125
2018 Q1	$16M	Buy	+5,927	New	+$14.4M	0.56%	65

Other funds holding VYNE

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management's VYNE Position: Q4 2019 in Review

Deerfield Management sold out of VYNE Therapeutics (VYNE) in Q4 2019, closing a stake of 1,384 shares — an estimated $446K sold.

Deerfield Management first reported a position in VYNE in Q1 2018 and held it in 4 quarters. The position peaked at $16M in Q1 2018. 54 funds tracked by Wall St. Rank hold VYNE as of Q4 2019.

Deerfield Management reported no remaining VYNE Therapeutics position as of Q4 2019 after selling out during the quarter.
Deerfield Management sold 1,384 VYNE Therapeutics shares in Q4 2019, an estimated $446K.
Deerfield Management first reported a position in VYNE Therapeutics in Q1 2018 and held it in 4 quarters.
Deerfield Management's VYNE Therapeutics position peaked at $16M in Q1 2018.
54 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2019.

Based on Deerfield Management's 13F filing for Q4 2019, filed 14 Feb 2020.